The performance of companies tied to the drug's past presents a complex investment landscape. While the initial boom generated substantial gains, generic alternatives have significantly eroded revenue. Investing in associated pharmaceutical firms now requires a careful assessment of intellectual property rights , evolving healthcare trends , and th